69 results on '"MacLennan, M."'
Search Results
2. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
- Author
-
Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.
- Published
- 2023
- Full Text
- View/download PDF
3. In search of tools for the use of Country-Image (CI) in the brand
- Author
-
Suter, M B, Giraldi, J M E, Borini, F M, MacLennan, M L F, Crescitelli, E', and Polo, E
- Abstract
Existing country image (CI) literature tends to focus on consumer behaviour. In contrast, this paper approaches CI from the point of view of the firm. In doing so, it seeks to identify the means by which international companies associate a brand with a specific country of origin in order to build brand values. In particular, it looks at the use of CI cues in brand strategies. The\ud paper is based on exploratory research comprising a case study of two contrasting companies from the cosmetics industry, Natura, a domestic company, and the French-owned L’Occitane, both of which draw on images of Brazil to build their brands. Specific elements of CI used in branding are identified, and the extent to which the use of these differs depending on the\ud origin of the owning company is explored. The cases suggest that CI can be exploited in different contexts. Through analysis of the elements used by both companies to build strong brands associated with the Brazilian CI—Natura Cosméticos and L’Occitane au Brésil—six tools are identified that can be combined by firms to deliver brand values, derived from any country, through the use of CI.
- Published
- 2017
4. Celt and Semite
- Author
-
MacLennan, M.
- Published
- 1905
- Full Text
- View/download PDF
5. PO-0842: Choosing the best heart sparing technique for breast and internal mammary chain radiotherapy
- Author
-
Ranger, A., Dunlop, A., Hutchinson, K., Maclennan, M., Convery, H., Chantler, H., Rose, C., Twyman, N., Donovan, E., Harris, E., Coles, C., and Kirby, A.
- Published
- 2017
- Full Text
- View/download PDF
6. OC-0452: Evaluation of a novel field placement algorithm for tangential internal mammary chain radiotherapy
- Author
-
Ranger, A., Dunlop, A., Maclennan, M., Donovan, E., Harris, E., Brigden, B., Knowles, C., Carr, K., Henegan, E., Francis, J., Bartlett, F., Somiah, N., Locke, I., Coles, C., and Kirby, A.
- Published
- 2017
- Full Text
- View/download PDF
7. OC-0265: Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy
- Author
-
Megias, D., Sydenham, M., Wheatley, D., Maclennan, M., Spezi, E., and Brunt, A.M.
- Published
- 2017
- Full Text
- View/download PDF
8. Coverage of axillary lymph node levels using standard radiotherapy fields for breast cancer patients – what are we actually treating?
- Author
-
Ranger, A., Kirby, A., Dunlop, A., Maclennan, M., and Coles, C.
- Published
- 2016
- Full Text
- View/download PDF
9. To what extent does tobacco expenditure crowd-out household expenditure in Bangladesh?
- Author
-
MacLennan, M., Ahmed, S., and Khan, J.
- Published
- 2015
- Full Text
- View/download PDF
10. Efficacy of injury prevention programs in adolescent sports: A Systematic Review
- Author
-
Soomro, N., Sanders, R., Hackett, D., Terrance, J., Freeston, J., Blanch, P., and Maclennan, M.
- Published
- 2014
- Full Text
- View/download PDF
11. Multimodal strategies to improve APACHE II score documentation
- Author
-
Donahoe, L, Kho, M, McDonald, E, Maclennan, M, McIntyre, S, Varga, P, and Cook, D
- Subjects
Poster Presentation - Published
- 2005
12. Restructuring the French Economy: Government and the Rise of Market Competition since World War II William James Adams
- Author
-
Maclennan, M. C.
- Published
- 1990
- Full Text
- View/download PDF
13. European interpretation of North American post mastectomy radiotherapy guideline update.
- Author
-
Kunkler, I.H., Dixon, J.M., Maclennan, M., and Russell, N.S.
- Subjects
RADIOTHERAPY treatment planning ,MASTECTOMY ,MEDICAL protocols ,MEDICAL care ,LYMPHADENECTOMY ,HEALTH outcome assessment ,CANCER relapse - Published
- 2017
- Full Text
- View/download PDF
14. PO75 IS THE BREAST CANCER GRADED PROGNOSTIC ASSESSMENT TOOL VALID IN SCOTTISH PATIENTS WITH SECONDARY BRAIN METASTASES?
- Author
-
Wells, L.A.R., Kerr, G., MacLennan, M., and Evans, T.K.A.
- Published
- 2013
- Full Text
- View/download PDF
15. Prophylactic G-CSF Use During Chemotherapy for Testicular Cancer
- Author
-
Scobie, S., MacLennan, M., McKenzie, J., Wells, L., Malik, J., and Law, A.
- Published
- 2013
- Full Text
- View/download PDF
16. Regional Policy in the United Kingdom.
- Author
-
MacLennan, M. C. and Robertson, D. J.
- Published
- 1969
- Full Text
- View/download PDF
17. In the Celtic Past Ethna Carbery
- Author
-
Maclennan, M.
- Published
- 1905
- Full Text
- View/download PDF
18. Transactions of the Gaelic Society of Inverness M. Maclennan
- Author
-
Maclennan, M.
- Published
- 1905
- Full Text
- View/download PDF
19. Foclóir Gaedhilge agus Béarla Patrick S. Dinneen
- Author
-
Maclennan, M.
- Published
- 1905
- Full Text
- View/download PDF
20. Studies in Early Irish History John Rhŷs
- Author
-
Maclennan, M.
- Published
- 1905
- Full Text
- View/download PDF
21. The St. Columba Scrip W. B. Stevenson
- Author
-
Maclennan, M.
- Published
- 1905
- Full Text
- View/download PDF
22. How a Region Grows: Area Development in the U. S. Economy H. S. Perloff Vera W. Dodds
- Author
-
MACLENNAN, M.
- Published
- 1964
23. Book Review: How a Region Grows: Area Development in the U.S. Economy by H. S. Perloff (with Vera W. Dodds), Committee for Economic Development, New York, Supplementary Paper No. 17, 1963, pp. 147, $2.25.
- Author
-
Maclennan, M.
- Published
- 1964
- Full Text
- View/download PDF
24. Streptococcus suis serotypes 7, 8 and 14 from diseased pigs in Scotland.
- Author
-
MacLennan, M., Foster, G., Dick, K., Smith, W. J., and Nielsen, B.
- Published
- 1996
- Full Text
- View/download PDF
25. ChemInform Abstract: Theoretical Evidence for P-S and P-N pπ-pπ Bonding Within the Heterocyclopentadienyl Framework.
- Author
-
MACLENNAN, M. T. and DARVESH, K. V.
- Published
- 1995
- Full Text
- View/download PDF
26. ChemInform Abstract: Reactions of 1,4-Dimethyl-4-nitrocyclohexa-2,5-dien-1-yl Acetates with Nitrogen Dioxide; Formation of Polynitro Cyclohexenyl Esters.
- Author
-
ABELL, A. D., HARTSHORN, M. P., MACLENNAN, M. E., ROBINSON, W. T., and WRIGHT, G. J.
- Published
- 1991
- Full Text
- View/download PDF
27. The impact of the titanium cranial hardware in proton single-field uniform dose plans.
- Author
-
Wang P, O'Grady FT, Janson M, Kim D, Choe KS, Grayden M, Bamberger CK, and Fan J
- Subjects
- Humans, Tomography, X-Ray Computed methods, Skull diagnostic imaging, Skull radiation effects, Titanium, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Phantoms, Imaging, Proton Therapy instrumentation, Proton Therapy methods, Radiotherapy, Intensity-Modulated methods, Organs at Risk radiation effects
- Abstract
Background: Neurosurgical cranial titanium mesh and screws are commonly encountered in postoperative radiation therapy. However, only a limited number of reports are available in the context of proton therapy, resulting in a lack of consensus among the proton centers regarding the protocol for handling the hardware., Purpose: This study is to examine the impact of the hardware in proton plans. The results serve as evidence for proton centers to generate standard operating procedures to manage the hardware in proton treatment., Methods: Plans with different gantry angles and material overrides are generated on the CT images of a phantom made of the hardware. The dose distributions of the plans with and without material override, at different depths are compared. Films and ionization chambers are used to measure the plans and the measurements are compared to the treatment planning system (TPS) calculations by gamma analysis., Results: There are some overdose and underdose regions downstream of the hardware. The overdose and underdose values are within a few percent of the prescribed dose when multiple fields with large hinge angles are used. The gamma analysis results show that the measurements agree with the TPS calculations within limits that are clinically relevant., Conclusion: The study has demonstrated the influence of the hardware on proton plans. Based on the result of this study, a standard operating procedure of managing the hardware has been implemented in our clinic., (© 2024 The Author(s). Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
28. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial.
- Author
-
Peters S, Gadgeel SM, Mok T, Nadal E, Kilickap S, Swalduz A, Cadranel J, Sugawara S, Chiu CH, Yu CJ, Moskovitz M, Tanaka T, Nersesian R, Shagan SM, Maclennan M, Mathisen M, Bhagawati-Prasad V, Diarra C, Assaf ZJ, Archer V, and Dziadziuszko R
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Aged, 80 and over, Liquid Biopsy, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Indazoles therapeutic use, Indazoles adverse effects, Benzamides therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Protein-Tyrosine Kinases antagonists & inhibitors, Protein-Tyrosine Kinases genetics
- Abstract
Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients. The Blood First Assay Screening Trial is a global, open-label, multicohort trial that evaluates the efficacy and safety of multiple therapies in patients with advanced/metastatic NSCLC and targetable alterations identified by liquid biopsy. We present data from Cohort D (ROS1-positive). Patients ≥18 years of age with stage IIIB/IV, ROS1-positive NSCLC detected by liquid biopsies received entrectinib 600 mg daily. At data cutoff (November 2021), 55 patients were enrolled and 54 had measurable disease. Cohort D met its primary endpoint: the confirmed objective response rate (ORR) by investigator was 81.5%, which was consistent with the ORR from the integrated analysis of entrectinib (investigator-assessed ORR, 73.4%; data cutoff May 2019, ≥12 months of follow-up). The safety profile of entrectinib was consistent with previous reports. These results demonstrate consistency with those from the integrated analysis of entrectinib in patients with ROS1-positive NSCLC identified by tissue-based testing, and support the clinical value of liquid biopsies to inform clinical decision-making. The integration of liquid biopsies into clinical practice provides patients with a less invasive diagnostic method than tissue-based testing and has faster turnaround times that may expedite the reaching of clinical decisions in the advanced/metastatic NSCLC setting. ClinicalTrials.gov registration: NCT03178552 ., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Meeting statement: Call to action for step-change in health behaviours.
- Author
-
Bach Habersaat K, Koylyu A, Likki T, Fietje N, Scherzer M, Snijders V, Mazhnaia A, Roy S, Berisha M, Basholli FM, Catic S, Nagyova I, Sivelä J, Cirulli F, Van der Biest L, Baros S, Lagarija ŠC, Schilling M, Nohlen HU, Forjaz MJ, Romay-Barja M, Üçüncü İ, Flaschberger E, Nikolić TK, Nesterova O, Lukmine I, Rivero-Montesdeoca Y, Loss J, Andreasyan D, Oikonomou MC, Godoy-Ramirez K, Karregård S, Murphy R, Niskanovic J, Van Brussel L, Telo de Arriaga M, Wojtyniak B, Price C, Altymysheva N, Jost KS, Berjaoui R, Saaristo P, Glazewska J, Topuridze M, Craig B, Mukhtarova P, Duishenkulova M, Pace S, MacLennan M, Bachanovikj M, Jakubowski E, Zeroug-Vial H, Gould A, Cutler A, Leurs M, Silitrari N, Bratu EC, Young J, Bianco VM, and Butler R
- Abstract
Background: Enabling, supporting and promoting positive health-related behaviours is critical in addressing the major public health challenges of our time, and the multifaceted nature of behaviours requires an evidence-based approach. This statement seeks to suggest how a much-needed enhanced use of behavioural and cultural science and insights for health could be advanced., Study Design and Methods: and methods: Public health authorities of Europe and Central Asia and international partner organizations in September 2023 met in Copenhagen, Denmark, to discuss the way forward. Drawing on 1) country reporting to WHO, 2) interview study with public health authorities and 3) the meeting deliberations, this meeting statement was developed., Results: The meeting statement presents a joint call for step-change accelerated use of evidence-based approaches for health behaviours. Actionable next steps for public health authorities and international and regional development partners in health are presented., Conclusions: The way forward involves increased resource allocation, integration of behavioural insights into health strategies, advocacy through case and cost-effectiveness examples and capacity building., (© 2024 Published by Elsevier Ltd on behalf of The Royal Society for Public Health.)
- Published
- 2024
- Full Text
- View/download PDF
30. Self-Massage Techniques for the Management of Pain and Mobility With Application to Resistance Training: A Brief Review.
- Author
-
MacLennan M, Ramirez-Campillo R, and Byrne PJ
- Subjects
- Humans, Range of Motion, Articular physiology, Massage methods, Myalgia therapy, Muscle, Skeletal physiology, Resistance Training, Sports
- Abstract
Abstract: MacLennan, M, Ramirez-Campillo, R, and Byrne, PJ. Self-massage techniques for the management of pain and mobility with application to resistance training: a brief review. J Strength Cond Res 37(11): 2314-2323, 2023-Fascial restrictions that occur in response to myofascial trigger points (MTrP), exercise-induced muscle damage (EIMD), and delayed onset of muscle soreness (DOMS) cause soft tissue to lose extensibility, which contributes to abnormal muscle mechanics, reduced muscle length, and decrements in joint range of motion (ROM) and actively contributes to musculoskeletal pain. Resistance training and in particular, weightlifting movements have unique mobility requirements imperative for movement efficacy and safety with ROM restrictions resulting in ineffective volume and intensity tolerance and dampened force output and power, which may lead to a failed lift or injury. Self-massage (SM) provides an expedient method to promote movement efficiency and reduce injury risk by improving ROM, muscular function, and reducing pain and allows athletes to continue to train at their desired frequency with minimal disruption from MTrPs-associated adverse effects. Thus, the aim of this review was to determine the efficacy of various self-massage tools in managing pain and mobility and to explore the potential benefits of SM on resistance training performance. Many SM devices are available for athletes to manage ROM restrictions and pain, including differing densities of foam rollers, roller massagers, tennis balls, and vibrating devices. To attenuate adverse training effects, a 10-to-20-minute bout consisting of 2-minute bouts of SM on the affected area may be beneficial. When selecting a SM device, athletes should note that foam rollers appear to be more effective than roller massagers, with vibrating foam rollers eliciting an increased reduction to pain perception, and tennis balls and soft massage balls were shown to be efficacious in targeting smaller affected areas., (Copyright © 2023 National Strength and Conditioning Association.)
- Published
- 2023
- Full Text
- View/download PDF
31. High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
- Author
-
Dziadziuszko R, Peled N, Mok T, Peters S, Aix SP, Alatorre-Alexander J, Vicuna BD, Maclennan M, Bhagawati-Prasad V, Shagan SM, Schleifman E, Ruf T, Mathisen MS, and Gadgeel SM
- Abstract
Introduction: This paper presents results from Cohort B (rearranged during transfection [ RET ], fusion-positive) of the Blood First Assay Screening Trial in patients with advanced non-small cell lung cancer (NSCLC) screened for genetic alterations using blood-based next-generation sequencing., Material and Methods: Adults with advanced RET fusion-positive NSCLC received alectinib 900 mg twice daily (BID) in Phase I. Enrolment closed prematurely with Phase II uninitiated., Results: Among eight treated patients, confirmed best overall responses in evaluable patients were stable disease (4/5) and progressive disease (1/5). One dose-limiting toxicity (death, unknown cause) was considered by the investigator to be related to treatment and underlying disease. Serious adverse events (SAEs) occurred in five patients, and SAEs that may be related to treatment occurred in two patients., Conclusions: Alectinib showed limited activity in advanced RET fusion-positive NSCLC, and further investigation was not conducted due to the development of selective RET inhibitors pralsetinib and selpercatinib. No new safety signals were observed, and the safety profile of alectinib was in line with previous reports at the 600 mg BID dose., Competing Interests: R.D: Advisory/consultancy fees from F. Hoffmann- La Roche, Ltd, Foundation Medicine, Pfizer, AstraZeneca, Novartis, Merck Sharp & Dohme, Karyopharm, and Boehringer Ingelheim. Honoraria from F. Hoffmann-La Roche, Ltd, AstraZeneca, and Amgen. Participated in data safety monitoring boards/advisory boards for F. Hoffmann-La Roche, Ltd, AstraZeneca, Amgen, and Merck Sharp & Dohme. N.P: Advisor and honorarium from, and research with, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Gaurdant Health, Merck, MSD, Novartis, NovellusDx, Pfizer, Roche, and Takeda. IP held for Volatile Organic Compounds for Detecting Cell Dysplasia and Genetic Alterations Associated With Lung Cancer; WO/2012/023138. T.M: Received fees for serving on advisory boards and consulting, and speakers fees and institutional grants and research support from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, and Pfizer. Fees for serving on advisory boards and consulting and speakers fees from ACEA Pharma, Amgen, Boehringer lngelheim, Daiichi Sankyo, Fishawack Facilitate, Ltd., Eli Lilly, OrigiMed Co. Ltd., Sanofi- Aventis; owns stock and has received fees for serving on advisory boards and board of directors/leadership roles from HutchMed; institutional grants and research support and fees for serving on advisory boards and consulting from Merck Serono and SFJ Pharmaceutical Ltd.; fees for serving on advisory boards, board of directors/leadership roles and consulting from Lunit, Inc.; fees for serving on advisory boards and for consulting from AbbVie, BerryOncology, Blueprint Medicines Corporation, C4 Therapeutics, CStone Pharmaceuticals, Curio Science, Eisai, Gilead Sciences, Inc., Gritstone Oncology, Inc., Guardant Health, Hengrui Therapeutics Inc., IQVIA, Janssen, lgnyta, Inc., lncyte Corporation, lnivata, Loxo Oncology Inc., Mirati Therapeutics Inc., Puma Biotechnology Inc., Vertex Pharmaceuticals, Yuhan Corporation; speakers fees and fees for consulting from Alpha Biopharma Co., Ltd., Amoy Diagnostics Co., Ltd., AstraZeneca (before 1 January 2019), BeiGene; fees for serving on advisory boards and institutional grants and research support from AstraZeneca, Gl Therapeutics, Inc., Takeda; institutional grants and research support from Roche, XCovery; speakers fees from Daz Group, InMed Medical Communication, Janssen, Liangyihui Network Technology Co., Ltd., Lucence Health Inc., MD Health Brazil, Medscape LLC, Merck Pharmaceuticals HK Ltd., P. Permanyer SL, PeerVoice, Physicians’ Education Resource, PrIME Oncology, Research to Practice, Roche Pharmaceuticals/Diagnostic/Foundation Medicine, Shanghai BeBirds Translation and Consulting Co., Ltd., Taiho, Takeda Oncology, touchIME; fees for consulting from Elevation Oncology, MoreHealth, Qiming Development (HK) Ltd., Roche Pharmaceuticals, Takeda Pharmaceuticals HK Ltd.; fees for serving on advisory boards for Roche/Genentech and Virtus Medical Group; fees for a board of directors/leadership role with AstraZeneca PLC; discloses serving on advisory boards (uncompensated) for geneDecode Co., Ltd.; owns stock from Act Genomics-Sanomics Group and Aurora Tele-Oncology Ltd.; declares uncompensated board of directors/leadership roles with the American Society of Clinical Oncology, Asian Thoracic Oncology Research Group, Chinese Lung Cancer Research Foundation Limited, Chinese Society of Clinical Oncology, Hong Kong Cancer Fund, Hong Kong Cancer Therapy Society, International Association for the Study of Lung Cancer (ending 30 April 2019), St. Stephen’s College and Preparatory School. S.P: Received institutional support for consulting or advising from AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, eCancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, IQVIA, Incyte, Janssen, Medscape, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, Oncology Education, PharmaMar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics and Takeda; institutional fees for speaking at company-sponsored public events for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, eCancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp & Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi and Takeda; and institutional grants and research support for the conduct of clinical trials from Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, GlaxoSmithKline, Illumina, Eli Lilly, Merck Sharp & Dohme, Merck Serono, Mirati Therapeutics Inc., Novartis, Pfizer, Phosplatin Therapeutics, and Roche/Genentech. S.P.A: Nothing to disclose. J.A: Received consulting fees from F. Hoffmann-La Roche, Ltd, AstraZeneca, Takeda, and Pfizer; honorarium from F. Hoffmann-La Roche, Ltd, AstraZeneca, Takeda; and meetings and/or travel support from F. Hoffmann- La Roche, Ltd, AstraZeneca, and MSD. B.D.V: Nothing to disclose. M.M: Employment at Syneos Health and works as a Study Statistician in FSP model for F. Hoffmann- La Roche, Ltd on a full-time basis. V.B: Roche employee and shareholder. Breath Analysis of Pulmonary Nodules. US20130150261 A1; Apparatus for treating a target site of a body; WO/2015/059646. S.M.S: Genentech employee and Roche shareholder. E.S: Genentech employee and Roche shareholder. T.R: Roche employee and shareholder. M.S.M: Genentech employee and Roche shareholder. S.M.G: Received fees for consulting from Genentech/Roche, Takeda, AstraZeneca, Pfizer, Daiichi Sankyo and Eli Lilly; served on an independent data monitoring committee for AstraZeneca., (Copyright © 2023 Termedia.)
- Published
- 2023
- Full Text
- View/download PDF
32. Evaluating the Typical Day-to-Day Variability of WHOOP-Derived Heart Rate Variability in Olympic Water Polo Athletes.
- Author
-
Bellenger CR, Miller D, Halson SL, Roach GD, Maclennan M, and Sargent C
- Subjects
- Adult, Athletes, Heart Rate physiology, Humans, Male, Reproducibility of Results, Young Adult, Sports, Water Sports
- Abstract
Heart rate (HR) and HR variability (HRV) can be used to infer readiness to perform exercise in athletic populations. Advancements in the photoplethysmography technology of wearable devices such as WHOOP allow for the frequent and convenient measurement of HR and HRV, and therefore enhanced application in athletes. However, it is important that the reliability of such technology is acceptable prior to its application in practical settings. Eleven elite male water polo players (age 28.8 ± 5.3 years [mean ± standard deviation]; height 190.3 ± 3.8 cm; body mass 95.0 ± 6.9 kg; international matches 117.9 ± 92.1) collected their HR and HRV daily via a WHOOP strap (WHOOP 3.0, CB Rank, Boston, MA, USA) over 16 weeks ahead of the 2021 Tokyo Olympic Games. The WHOOP strap quantified HR and HRV via wrist-based photoplethysmography during overnight sleep periods. The weekly (i.e., 7-day) coefficient of variation in lnRMSSD (lnRMSSD
CV ) and HR (HRCV ) was calculated as a measure of day-to-day variability in lnRMSSD and HR, and presented as a mean of the entire recording period. The mean weekly lnRMSSDCV and HRCV over the 16-week period was 5.4 ± 0.7% (mean ± 95% confidence intervals) and 7.6 ± 1.3%, respectively. The day-to-day variability in WHOOP-derived lnRMSSD and HR is within or below the range of day-to-day variability in alternative lnRMSSD (~3-13%) and HR (~10-11%) assessment protocols, indicating that the assessment of HR and HRV by WHOOP does not introduce any more variability than that which is naturally present in these variables.- Published
- 2022
- Full Text
- View/download PDF
33. Validation of the NeuMoDx™ SARS-CoV-2 assay with COPAN eNAT® and E&O Viral PCR Sample Solution collection media types in comparison with other validated SARS-CoV-2 RNA assays.
- Author
-
Baird D, Muir A, Logan L, and MacLennan M
- Subjects
- COVID-19 Testing, Humans, Polymerase Chain Reaction, RNA, Viral genetics, Sensitivity and Specificity, COVID-19 diagnosis, SARS-CoV-2 genetics
- Abstract
Objectives: This study aimed to confirm NeuMoDx™ SARS-CoV-2 assay (NeuMoDx assay) functionality using off-label collection media, determine assay performance versus other SARS-CoV-2 RNA assays, and assess any cross-reactivity with other respiratory viruses (human coronavirus NL63, influenza, and respiratory syncytial virus)., Methods: Nasopharyngeal swab samples in off-label collection media and external quality assessment (EQA) samples were dual-tested, first using either the RealStar® SARS-CoV-2 reverse transcriptase polymerase chain reaction assay or the QIAstat-Dx® Respiratory SARS-CoV-2 Panel and then using the NeuMoDx assay. Samples found to be positive for respiratory viruses and negative for SARS-CoV-2 were then tested using the NeuMoDx assay to assess cross-reactivity., Results: Overall, 274 samples (244 patient and 30 EQA samples) were dual-tested; 154 were SARS-CoV-2 positive and 120 were negative. No false-positive or false-negative results were identified, regardless of collection medium used. The NeuMoDx assay sensitivity was 100% (95% confidence interval [CI] 97.63-100.00) and the specificity was 100% (95% CI 96.97-100.00). The assay did not exhibit any cross-reactivity with other respiratory viruses., Conclusion: The NeuMoDx assay demonstrated high sensitivity and specificity on a platform well-suited for fully automated SARS-CoV-2 testing., Competing Interests: Declaration of Competing Interest The authors have no competing interests to declare., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. Evaluating Uncertainty and Modes of Variability for Antarctic Atmospheric Rivers.
- Author
-
Shields CA, Wille JD, Marquardt Collow AB, Maclennan M, and Gorodetskaya IV
- Abstract
Antarctic atmospheric rivers (ARs) are driven by their synoptic environments and lead to profound and varying impacts along the coastlines and over the continent. The definition and detection of ARs over Antarctica accounts for large uncertainty in AR metrics, and consequently, impacts quantification. We find that Antarctic-specific detection tools consistently capture the AR footprint inland over ice sheets, whereas most global detection tools do not. Large-scale synoptic environments and associated ARs, however, are broadly consistent across detection tools. Using data from the Atmospheric River Tracking Method Intercomparison Project and global reanalyses, we quantify the uncertainty in Antarctic AR metrics and evaluate large-scale environments in the context of decadal and interannual modes of variability. The Antarctic western hemisphere has stronger connections to both decadal and interannual modes of variability compared to East Antarctica, and the Indian Ocean Dipole's influence on Antarctic ARs is stronger while in phase with El Nino Southern Oscillation., (© 2022. The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
35. Undifferentiated presentation of unilateral agenesis of a cervical pedicle and a contiguous vertebral hemangioma: illustrative case.
- Author
-
Alsuwaihel M, El-Mughayyar D, MacLennan M, and Attabib N
- Abstract
Background: Unilateral agenesis of a cervical pedicle is a known rare entity that has been well described over the past 70 years. It is usually an incidental or minimally symptomatic presentation with no significant clinical repercussion. No previous report has described concurrent non-osseous developmental abnormalities alongside this unique pathology., Observations: This case reported a cervical hemangioma with associated unilateral pedicle agenesis and an incidental finding of callosal dysgenesis and lipoma. The initial presentation consisted solely of persistent neck pain, with cervical radiography illustrating significant kyphotic deformity secondary to apparent anterolisthesis of C3-C4. The patient underwent a combined approach: anterior cervical corpectomy at C4-C5 with supplemental posterior fusion. The authors provided a review of the literature concerning developmental pedicle abnormalities and vertebral hemangioma. Pedicle agenesis is known to be associated with multiple pathologies, but the authors have not found evidence of a clinical paradigm consisting of a vertebral hemangioma in the presence of cervical pedicle agenesis, callosal dysgenesis, or callosal lipoma., Lessons: Careful evaluation of radiographs with appropriate subsequent multimodal imaging is key to identifying unique pathologies in the spine that complement a patient's history and clinical findings. If multiple abnormalities are noted, a novel clinical etiology or syndrome must be considered.
- Published
- 2022
- Full Text
- View/download PDF
36. Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis.
- Author
-
Stares M, Purshouse K, Knowles G, Haigh R, Irvine J, Gatenby A, Patton R, McGinty J, Christie A, MacLennan M, Barrie C, and Clive S
- Subjects
- Aged, Female, Humans, Male, Prospective Studies, Time Factors, Treatment Outcome, Neoplasms, Unknown Primary epidemiology
- Abstract
Background: In the United Kingdom, national guidance published in 2010 recommended the establishment of specialist teams to improve clinical pathways for patients presenting with malignancies of undefined primary origin (MUO) and cancer of unknown primary (CUP). This study sought to define outcomes of patients referred to a regional MUO/CUP service., Methods: Data were collected prospectively on all patients (n = 1225) referred to a regional CUP team over a 10-year period. Patient demographics, clinical, pathological and outcome data were recorded and analysed., Results: Confirmed CUP (cCUP) was diagnosed in 25% of patients. A primary metastatic cancer was identified in 36%, 5% were diagnosed with provisional CUP (pCUP), 27% retained the diagnosis of MUO and in 8% a non-cancer diagnosis was made. Median survival was low in all patients with a final malignant diagnosis: primary identified 9.0 months, cCUP 4.0 months, pCUP 1.5 months and MUO 1.5 months., Conclusions: Patients presenting with MUO have poor outcomes irrespective of the final diagnosis. These patients need a patient-centred, streamlined, rapid diagnostic pathway. There are clear benefits to primary and secondary care teams having access to a dedicated, multidisciplinary MUO/CUP service, with clinical nurse specialists supporting the patients, to help facilitate this pathway and ensure early oncology review., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
37. Mutational bias in spermatogonia impacts the anatomy of regulatory sites in the human genome.
- Author
-
Kaiser VB, Talmane L, Kumar Y, Semple F, MacLennan M, FitzPatrick DR, Taylor MS, and Semple CA
- Subjects
- Binding Sites, Chromatin Immunoprecipitation Sequencing, Histone-Lysine N-Methyltransferase genetics, Humans, Male, Mutation, Genome, Human, Spermatogonia metabolism
- Abstract
Mutation in the germline is the ultimate source of genetic variation, but little is known about the influence of germline chromatin structure on mutational processes. Using ATAC-seq, we profile the open chromatin landscape of human spermatogonia, the most proliferative cell type of the germline, identifying transcription factor binding sites (TFBSs) and PRDM9 binding sites, a subset of which will initiate meiotic recombination. We observe an increase in rare structural variant (SV) breakpoints at PRDM9-bound sites, implicating meiotic recombination in the generation of structural variation. Many germline TFBSs, such as NRF1, are also associated with increased rates of SV breakpoints, apparently independent of recombination. Singleton short insertions (≥5 bp) are highly enriched at TFBSs, particularly at sites bound by testis active TFs, and their rates correlate with those of structural variant breakpoints. Short insertions often duplicate the TFBS motif, leading to clustering of motif sites near regulatory regions in this male-driven evolutionary process. Increased mutation loads at germline TFBSs disproportionately affect neural enhancers with activity in spermatogonia, potentially altering neurodevelopmental regulatory architecture. Local chromatin structure in spermatogonia is thus pervasive in shaping both evolution and disease., (© 2021 Kaiser et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2021
- Full Text
- View/download PDF
38. Use of fluorescence to visualize response to iloprost treatment for frostbite.
- Author
-
MacLennan M, Poole A, and Gauthier J
- Subjects
- Coloring Agents therapeutic use, Fluorescence, Humans, Male, Middle Aged, Optical Imaging methods, Treatment Outcome, Vasodilator Agents administration & dosage, Frostbite drug therapy, Iloprost administration & dosage, Indocyanine Green therapeutic use
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2021
- Full Text
- View/download PDF
39. Management of severe frostbite with iloprost, alteplase and heparin: a Yukon case series.
- Author
-
Poole A, Gauthier J, and MacLennan M
- Subjects
- Adult, Alcohol Drinking epidemiology, Emergency Medical Services methods, Female, Fibrinolytic Agents administration & dosage, Fibrinolytic Agents adverse effects, Humans, Male, Outcome and Process Assessment, Health Care, Retrospective Studies, Risk Factors, Severity of Illness Index, Sports statistics & numerical data, Time-to-Treatment standards, Vasodilator Agents administration & dosage, Vasodilator Agents adverse effects, Yukon Territory epidemiology, Amputation, Surgical methods, Amputation, Surgical statistics & numerical data, Fingers pathology, Fingers surgery, Frostbite diagnosis, Frostbite epidemiology, Frostbite surgery, Frostbite therapy, Heparin administration & dosage, Heparin adverse effects, Iloprost administration & dosage, Iloprost adverse effects, Tissue Plasminogen Activator administration & dosage, Tissue Plasminogen Activator adverse effects
- Abstract
Background: We identified the need to modernize frostbite management in our northern centre and implemented a treatment protocol in 2015. Our aim was to describe the clinical course of patients presenting to the hospital since the implementation of the protocol., Methods: This was a retrospective case series from Whitehorse General Hospital, Whitehorse, Yukon Territory, Canada. We reviewed the charts of patients who presented to the hospital with grade 2-4 frostbite and were treated as per our protocol between Feb. 9, 2015, and Feb. 8, 2020. Patients with grade 2-4 frostbite received iloprost; in addition, those with grade 4 frostbite received alteplase and heparin. We determined the number of digits affected and salvaged, and the time from presentation to the emergency department to treatment initiation. We also examined patients' demographic characteristics, predisposing events, frostbite severity and adverse drug reactions., Results: In 22 patients treated for grade 2-4 frostbite, 142 digits were affected: 59 with grade 2 frostbite, 25 with grade 3 frostbite and 58 with grade 4 frostbite; of the 142, 113 (79.6%) were salvaged. All 29 digits amputated had grade 4 frostbite. The mean time from presentation to iloprost initiation was reduced from 32.9 hours in 2015 to 3.0 hours in 2020. Sports (10 cases [45%]) and alcohol use (6 [27%]) were the most common precipitating events, with alcohol use tending to result in more severe injury (grade 4 in 5 of 6 cases). Adverse reactions with iloprost (e.g., headache) were common but mild. Adverse reactions with alteplase (e.g., bleeding) were less common but of greater clinical significance., Interpretation: Over the study period, our protocol contributed to improvement in frostbite care at our institution, resulting in a digit salvage rate comparable to other published results. Our 5-year experience shows that advanced medical care of frostbite can be achieved, even at a rural centre., Competing Interests: Competing interests: Josianne Gauthier is employed by the Whitehorse General Hospital (Yukon Hospital Corporation). No other competing interests were declared., (© 2021 CMA Joule Inc. or its licensors.)
- Published
- 2021
- Full Text
- View/download PDF
40. Tex19.1 inhibits the N-end rule pathway and maintains acetylated SMC3 cohesin and sister chromatid cohesion in oocytes.
- Author
-
Reichmann J, Dobie K, Lister LM, Crichton JH, Best D, MacLennan M, Read D, Raymond ES, Hung CC, Boyle S, Shirahige K, Cooke HJ, Herbert M, and Adams IR
- Subjects
- Aneuploidy, Animals, Cell Lineage genetics, Chromatids genetics, Chromosome Segregation genetics, Female, Germ Cells growth & development, Humans, Meiosis genetics, Mice, Mice, Knockout, Oocytes growth & development, Oocytes metabolism, Cohesins, Cell Cycle Proteins genetics, Chondroitin Sulfate Proteoglycans genetics, Chromosomal Proteins, Non-Histone genetics, RNA-Binding Proteins genetics, Sister Chromatid Exchange genetics, Ubiquitin-Protein Ligases genetics
- Abstract
Age-dependent oocyte aneuploidy, a major cause of Down syndrome, is associated with declining sister chromatid cohesion in postnatal oocytes. Here we show that cohesion in postnatal mouse oocytes is regulated by Tex19.1. We show Tex19.1-/- oocytes have defects maintaining chiasmata, missegregate their chromosomes during meiosis, and transmit aneuploidies to the next generation. Furthermore, we show that mouse Tex19.1 inhibits N-end rule protein degradation mediated by its interacting partner UBR2, and that Ubr2 itself has a previously undescribed role in negatively regulating the acetylated SMC3 subpopulation of cohesin in mitotic somatic cells. Lastly, we show that acetylated SMC3 is associated with meiotic chromosome axes in mouse oocytes, and that this population of cohesin is specifically depleted in the absence of Tex19.1. These findings indicate that Tex19.1 regulates UBR protein activity to maintain acetylated SMC3 and sister chromatid cohesion in postnatal oocytes and prevent aneuploidy from arising in the female germline., (© 2020 Reichmann et al.)
- Published
- 2020
- Full Text
- View/download PDF
41. Measuring the efficiency of health systems in Asia: a data envelopment analysis.
- Author
-
Ahmed S, Hasan MZ, MacLennan M, Dorin F, Ahmed MW, Hasan MM, Hasan SM, Islam MT, and Khan JAM
- Subjects
- Asia, Benchmarking, Health Expenditures, Humans, Outcome and Process Assessment, Health Care, Quality Improvement organization & administration, Quality Indicators, Health Care, Delivery of Health Care methods, Delivery of Health Care organization & administration, Efficiency, Organizational standards
- Abstract
Objective: This study aims to estimate the technical efficiency of health systems in Asia., Settings: The study was conducted in Asian countries., Methods: We applied an output-oriented data envelopment analysis (DEA) approach to estimate the technical efficiency of the health systems in Asian countries. The DEA model used per-capita health expenditure (all healthcare resources as a proxy) as input variable and cross-country comparable health outcome indicators (eg, healthy life expectancy at birth and infant mortality per 1000 live births) as output variables. Censored Tobit regression and smoothed bootstrap models were used to observe the associated factors with the efficiency scores. A sensitivity analysis was performed to assess the consistency of these efficiency scores., Results: The main findings of this paper demonstrate that about 91.3% (42 of 46 countries) of the studied Asian countries were inefficient with respect to using healthcare system resources. Most of the efficient countries belonged to the high-income group (Cyprus, Japan, and Singapore) and only one country belonged to the lower middle-income group (Bangladesh). Through improving health system efficiency, the studied high-income, upper middle-income, low-income and lower middle-income countries can improve health system outcomes by 6.6%, 8.6% and 8.7%, respectively, using the existing level of resources. Population density, bed density, and primary education completion rate significantly influenced the efficiency score., Conclusion: The results of this analysis showed inefficiency of the health systems in most of the Asian countries and imply that many countries may improve their health system efficiency using the current level of resources. The identified inefficient countries could pay attention to benchmarking their health systems within their income group or other within similar types of health systems., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
42. A Dosimetric Comparison of Breast Radiotherapy Techniques to Treat Locoregional Lymph Nodes Including the Internal Mammary Chain.
- Author
-
Ranger A, Dunlop A, Hutchinson K, Convery H, Maclennan MK, Chantler H, Twyman N, Rose C, McQuaid D, Amos RA, Griffin C, deSouza NM, Donovan E, Harris E, Coles CE, and Kirby A
- Subjects
- Breast pathology, Breast Neoplasms pathology, Female, Humans, Middle Aged, Radiometry methods, Breast diagnostic imaging, Breast Neoplasms radiotherapy, Lymph Nodes radiation effects
- Abstract
Aims: Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival benefits of IMC radiotherapy, doses to the heart and lung should be minimised. This dosimetry study compared the ability of three-dimensional conformal radiotherapy, arc therapy and proton beam therapy (PBT) techniques with and without breath-hold to achieve target volume constraints while minimising dose to organs at risk (OARs)., Materials and Methods: In 14 patients' datasets, seven IMC radiotherapy techniques were compared: wide tangent (WT) three-dimensional conformal radiotherapy, volumetric-modulated arc therapy (VMAT) and PBT, each in voluntary deep inspiratory breath-hold (vDIBH) and free breathing (FB), and tomotherapy in FB only. Target volume coverage and OAR doses were measured for each technique. These were compared using a one-way ANOVA with all pairwise comparisons tested using Bonferroni's multiple comparisons test, with adjusted P-values ≤ 0.05 indicating statistical significance., Results: One hundred per cent of WT(vDIBH), 43% of WT(FB), 100% of VMAT(vDIBH), 86% of VMAT(FB), 100% of tomotherapy FB and 100% of PBT plans in vDIBH and FB passed all mandatory constraints. However, coverage of the IMC with 90% of the prescribed dose was significantly better than all other techniques using VMAT(vDIBH), PBT(vDIBH) and PBT(FB) (mean IMC coverage ± 1 standard deviation = 96.0% ± 4.3, 99.8% ± 0.3 and 99.0% ± 0.2, respectively). The mean heart dose was significantly reduced in vDIBH compared with FB for both the WT (P < 0.0001) and VMAT (P < 0.0001) techniques. There was no advantage in target volume coverage or OAR doses for PBT(vDIBH) compared with PBT(FB)., Conclusions: Simple WT radiotherapy delivered in vDIBH achieves satisfactory coverage of the IMC while meeting heart and lung dose constraints. However, where higher isodose coverage is required, VMAT(vDIBH) is the optimal photon technique. The lowest OAR doses are achieved by PBT, in which the use of vDIBH does not improve dose statistics., (Crown Copyright © 2018. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
43. Mobilization of LINE-1 retrotransposons is restricted by Tex19.1 in mouse embryonic stem cells.
- Author
-
MacLennan M, García-Cañadas M, Reichmann J, Khazina E, Wagner G, Playfoot CJ, Salvador-Palomeque C, Mann AR, Peressini P, Sanchez L, Dobie K, Read D, Hung CC, Eskeland R, Meehan RR, Weichenrieder O, García-Pérez JL, and Adams IR
- Subjects
- Animals, Gene Knockout Techniques, Mice, Nuclear Proteins genetics, Protein Binding, Proteolysis, Ubiquitin-Protein Ligases metabolism, Ubiquitination, Long Interspersed Nucleotide Elements, Mouse Embryonic Stem Cells physiology, Nuclear Proteins metabolism, RNA-Binding Proteins metabolism, Recombination, Genetic
- Abstract
Mobilization of retrotransposons to new genomic locations is a significant driver of mammalian genome evolution, but these mutagenic events can also cause genetic disorders. In humans, retrotransposon mobilization is mediated primarily by proteins encoded by LINE-1 (L1) retrotransposons, which mobilize in pluripotent cells early in development. Here we show that TEX19.1, which is induced by developmentally programmed DNA hypomethylation, can directly interact with the L1-encoded protein L1-ORF1p, stimulate its polyubiquitylation and degradation, and restrict L1 mobilization. We also show that TEX19.1 likely acts, at least in part, through promoting the activity of the E3 ubiquitin ligase UBR2 towards L1-ORF1p. Moreover, loss of Tex19.1 increases L1-ORF1p levels and L1 mobilization in pluripotent mouse embryonic stem cells, implying that Tex19.1 prevents de novo retrotransposition in the pluripotent phase of the germline cycle. These data show that post-translational regulation of L1 retrotransposons plays a key role in maintaining trans-generational genome stability in mammals.
- Published
- 2017
- Full Text
- View/download PDF
44. Tex19.1 promotes Spo11-dependent meiotic recombination in mouse spermatocytes.
- Author
-
Crichton JH, Playfoot CJ, MacLennan M, Read D, Cooke HJ, and Adams IR
- Subjects
- Animals, Chromosome Pairing, Chromosomes, Mammalian genetics, Chromosomes, Mammalian metabolism, Endodeoxyribonucleases genetics, Male, Meiotic Prophase I genetics, Mice, Mice, Inbred C57BL, Nuclear Proteins genetics, Promoter Regions, Genetic, RNA-Binding Proteins, Recombination, Genetic, Ubiquitin-Protein Ligases genetics, Endodeoxyribonucleases metabolism, Meiosis genetics, Nuclear Proteins metabolism, Spermatocytes metabolism, Ubiquitin-Protein Ligases metabolism
- Abstract
Meiosis relies on the SPO11 endonuclease to generate the recombinogenic DNA double strand breaks (DSBs) required for homologous chromosome synapsis and segregation. The number of meiotic DSBs needs to be sufficient to allow chromosomes to search for and find their homologs, but not excessive to the point of causing genome instability. Here we report that the mammal-specific gene Tex19.1 promotes Spo11-dependent recombination in mouse spermatocytes. We show that the chromosome asynapsis previously reported in Tex19.1-/- spermatocytes is preceded by reduced numbers of recombination foci in leptotene and zygotene. Tex19.1 is required for normal levels of early Spo11-dependent recombination foci during leptotene, but not for upstream events such as MEI4 foci formation or accumulation of H3K4me3 at recombination hotspots. Furthermore, we show that mice carrying mutations in Ubr2, which encodes an E3 ubiquitin ligase that interacts with TEX19.1, phenocopy the Tex19.1-/- recombination defects. These data suggest that Tex19.1 and Ubr2 are required for mouse spermatocytes to accumulate sufficient Spo11-dependent recombination to ensure that the homology search is consistently successful, and reveal a hitherto unknown genetic pathway promoting meiotic recombination in mammals.
- Published
- 2017
- Full Text
- View/download PDF
45. Benefit incidence analysis of healthcare in Bangladesh - equity matters for universal health coverage.
- Author
-
Khan JA, Ahmed S, MacLennan M, Sarker AR, Sultana M, and Rahman H
- Subjects
- Bangladesh, Government Programs, Health Personnel statistics & numerical data, Humans, Poverty, Socioeconomic Factors, Surveys and Questionnaires, Healthcare Disparities, Insurance, Health, Private Sector statistics & numerical data, Universal Health Insurance
- Abstract
Background: Equity in access to and utilization of healthcare is an important goal for any health system and an essential prerequisite for achieving Universal Health Coverage for any country., Objectives: This study investigated the extent to which health benefits are distributed across socioeconomic groups; and how different types of providers contribute to inequity in health benefits of Bangladesh., Methodology: The distribution of health benefits across socioeconomic groups was estimated using concentration indices. Health benefits from three types of formal providers were analysed (public, private and NGO providers), separated into rural and urban populations. Decomposition of concentration indices into types of providers quantified the relative contribution of providers to the overall distribution of benefits across socioeconomic groups. Eventually, the distribution of benefits was compared to the distribution of healthcare need (proxied by 'self-reported illness and symptoms') across socioeconomic groups. Data from the latest Household Income and Expenditure Survey, 2010 and WHO-CHOICE were used., Results: An overall pro-rich distribution of healthcare benefits was observed (CI = 0.229, t -value = 9.50). Healthcare benefits from private providers (CI = 0.237, t -value = 9.44) largely favoured the richer socioeconomic groups. Little evidence of inequity in benefits was found in public (CI = 0.044, t -value = 2.98) and NGO (CI = 0.095, t -value = 0.54) providers. Private providers contributed by 95.9% to overall inequity. The poorest socioeconomic group with 21.8% of the need for healthcare received only 12.7% of the benefits, while the richest group with 18.0% of the need accounted for 32.8% of the health benefits., Conclusion: Overall healthcare benefits in Bangladesh were pro-rich, particularly because of health benefits from private providers. Public providers were observed to contribute relatively slightly to inequity. The poorest (richest) people with largest (least) need for healthcare actually received lower (higher) benefits. When working to achieve Universal Health Coverage in Bangladesh, particular consideration should be given to ensuring that private sector care is more equitable., (© The Author 2016. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com)
- Published
- 2017
- Full Text
- View/download PDF
46. A SLM2 Feedback Pathway Controls Cortical Network Activity and Mouse Behavior.
- Author
-
Ehrmann I, Gazzara MR, Pagliarini V, Dalgliesh C, Kheirollahi-Chadegani M, Xu Y, Cesari E, Danilenko M, Maclennan M, Lowdon K, Vogel T, Keskivali-Bond P, Wells S, Cater H, Fort P, Santibanez-Koref M, Middei S, Sette C, Clowry GJ, Barash Y, Cunningham MO, and Elliott DJ
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, Behavior, Animal physiology, Calcium-Binding Proteins, Homeostasis genetics, Mice, Mice, Knockout, Neural Cell Adhesion Molecules genetics, RNA Precursors genetics, RNA-Binding Proteins metabolism, Synapses physiology, Alternative Splicing genetics, Nerve Net, Pyramidal Cells metabolism, RNA-Binding Proteins genetics, Synapses genetics
- Abstract
The brain is made up of trillions of synaptic connections that together form neural networks needed for normal brain function and behavior. SLM2 is a member of a conserved family of RNA binding proteins, including Sam68 and SLM1, that control splicing of Neurexin1-3 pre-mRNAs. Whether SLM2 affects neural network activity is unknown. Here, we find that SLM2 levels are maintained by a homeostatic feedback control pathway that predates the divergence of SLM2 and Sam68. SLM2 also controls the splicing of Tomosyn2, LysoPLD/ATX, Dgkb, Kif21a, and Cask, each of which are important for synapse function. Cortical neural network activity dependent on synaptic connections between SLM2-expressing-pyramidal neurons and interneurons is decreased in Slm2-null mice. Additionally, these mice are anxious and have a decreased ability to recognize novel objects. Our data reveal a pathway of SLM2 homeostatic auto-regulation controlling brain network activity and behavior., (Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
47. Oocyte development, meiosis and aneuploidy.
- Author
-
MacLennan M, Crichton JH, Playfoot CJ, and Adams IR
- Subjects
- Animals, Chromosome Segregation, Crossing Over, Genetic, Female, Humans, Oogenesis, Recombination, Genetic, Meiosis, Oocytes physiology, Trisomy
- Abstract
Meiosis is one of the defining events in gametogenesis. Male and female germ cells both undergo one round of meiotic cell division during their development in order to reduce the ploidy of the gametes, and thereby maintain the ploidy of the species after fertilisation. However, there are some aspects of meiosis in the female germline, such as the prolonged arrest in dictyate, that appear to predispose oocytes to missegregate their chromosomes and transmit aneuploidies to the next generation. These maternally-derived aneuploidies are particularly problematic in humans where they are major contributors to miscarriage, age-related infertility, and the high incidence of Down's syndrome in human conceptions. This review will discuss how events that occur in foetal oocyte development and during the oocytes' prolonged dictyate arrest can influence meiotic chromosome segregation and the incidence of aneuploidy in adult oocytes., (Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
48. The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis.
- Author
-
Verguet S, Gauvreau CL, Mishra S, MacLennan M, Murphy SM, Brouwer ED, Nugent RA, Zhao K, Jha P, and Jamison DT
- Subjects
- Adolescent, Adult, Aged, China, Cost-Benefit Analysis, Health Status, Humans, Income, Male, Middle Aged, Models, Economic, Smoking economics, Young Adult, Public Health, Smoking Cessation economics, Smoking Prevention, Taxes, Tobacco Products economics
- Abstract
Background: In China, there are more than 300 million male smokers. Tobacco taxation reduces smoking-related premature deaths and increases government revenues, but has been criticised for disproportionately affecting poorer people. We assess the distributional consequences (across different wealth quintiles) of a specific excise tax on cigarettes in China in terms of both financial and health outcomes., Methods: We use extended cost-effectiveness analysis methods to estimate, across income quintiles, the health benefits (years of life gained), the additional tax revenues raised, the net financial consequences for households, and the financial risk protection provided to households, that would be caused by a 50% increase in tobacco price through excise tax fully passed onto tobacco consumers. For our modelling analysis, we used plausible values for key parameters, including an average price elasticity of demand for tobacco of -0·38, which is assumed to vary from -0·64 in the poorest quintile to -0·12 in the richest, and we considered only the male population, which constitutes the overwhelming majority of smokers in China., Findings: Our modelling analysis showed that a 50% increase in tobacco price through excise tax would lead to 231 million years of life gained (95% uncertainty range 194-268 million) over 50 years (a third of which would be gained in the lowest income quintile), a gain of US$703 billion ($616-781 billion) of additional tax revenues from the excise tax (14% of which would come from the lowest income quintile, compared with 24% from the highest income quintile). The excise tax would increase overall household expenditures on tobacco by $376 billion ($232-505 billion), but decrease these expenditures by $21 billion (-$83 to $5 billion) in the lowest income quintile, and would reduce expenditures on tobacco-related disease by $24·0 billion ($17·3-26·3 billion, 28% of which would benefit the lowest income quintile). Finally, it would provide financial risk protection worth $1·8 billion ($1·2-2·3 billion), mainly concentrated (74%) in the lowest income quintile., Interpretation: Increased tobacco taxation can be a pro-poor policy instrument that brings substantial health and financial benefits to households in China., Funding: Bill & Melinda Gates Foundation and Dalla Lana School of Public Health., (Copyright © 2015 Verguet et al. Open access article distributed under the terms of CC BY-NC-SA. Published by .. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
49. Defending the genome from the enemy within: mechanisms of retrotransposon suppression in the mouse germline.
- Author
-
Crichton JH, Dunican DS, Maclennan M, Meehan RR, and Adams IR
- Subjects
- Animals, DNA Methylation, Embryonic Stem Cells cytology, Embryonic Stem Cells metabolism, Germ Cells cytology, Humans, Mice, Pluripotent Stem Cells cytology, Pluripotent Stem Cells metabolism, RNA, Small Interfering metabolism, Genome, Germ Cells metabolism, Retroelements genetics
- Abstract
The viability of any species requires that the genome is kept stable as it is transmitted from generation to generation by the germ cells. One of the challenges to transgenerational genome stability is the potential mutagenic activity of transposable genetic elements, particularly retrotransposons. There are many different types of retrotransposon in mammalian genomes, and these target different points in germline development to amplify and integrate into new genomic locations. Germ cells, and their pluripotent developmental precursors, have evolved a variety of genome defence mechanisms that suppress retrotransposon activity and maintain genome stability across the generations. Here, we review recent advances in understanding how retrotransposon activity is suppressed in the mammalian germline, how genes involved in germline genome defence mechanisms are regulated, and the consequences of mutating these genome defence genes for the developing germline.
- Published
- 2014
- Full Text
- View/download PDF
50. Menhaden oil, but not safflower or soybean oil, aids in restoring the polyunsaturated fatty acid profile in the novel delta-6-desaturase null mouse.
- Author
-
Monteiro J, Li FJ, Maclennan M, Rabalski A, Moghadasian MH, Nakamura MT, and Ma DW
- Subjects
- Animals, Delta-5 Fatty Acid Desaturase, Fatty Acid Desaturases metabolism, Linoleic Acid blood, Linoleoyl-CoA Desaturase genetics, Lipid Metabolism, Liver metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Phospholipids blood, Phospholipids metabolism, alpha-Linolenic Acid blood, Fish Oils administration & dosage, Linoleic Acid metabolism, Linoleoyl-CoA Desaturase deficiency, Safflower Oil administration & dosage, Soybean Oil administration & dosage, alpha-Linolenic Acid metabolism
- Abstract
Background: Polyunsaturated fatty acids (PUFA) have diverse biological effects, from promoting inflammation to preventing cancer and heart disease. Growing evidence suggests that individual PUFA may have independent effects in health and disease. The individual roles of the two essential PUFA, linoleic acid (LA) and α-linolenic acid (ALA), have been difficult to discern from the actions of their highly unsaturated fatty acid (HUFA) downstream metabolites. This issue has recently been addressed through the development of the Δ-6 desaturase knock out (D6KO) mouse, which lacks the rate limiting Δ-6 desaturase enzyme and therefore cannot metabolize LA or ALA. However, a potential confounder in this model is the production of novel Δ-5 desaturase (D5D) derived fatty acids when D6KO mice are fed diets containing LA and ALA, but void of arachidonic acid., Objective: The aim of the present study was to characterize how the D6KO model differentially responds to diets containing the essential n-6 and n-3 PUFA, and whether the direct provision of downstream HUFA can rescue the phenotype and prevent the production of D5D fatty acids., Methodology: Liver and serum phospholipid (PL) fatty acid composition was examined in D6KO and wild type mice fed i) 10% safflower oil diet (SF, LA rich) ii) 10% soy diet (SO, LA+ALA) or iii) 3% menhaden oil +7% SF diet (MD, HUFA rich) for 28 days (n = 3-7/group)., Results: Novel D5D fatty acids were found in liver PL of D6KO fed SF or SO-fed mice, but differed in the type of D5D fatty acid depending on diet. Conversely, MD-fed D6KO mice had a liver PL fatty acid profile similar to wild-type mice., Conclusions: Through careful consideration of the dietary fatty acid composition, and especially the HUFA content in order to prevent the synthesis of D5D fatty acids, the D6KO model has the potential to elucidate the independent biological and health effects of the parent n-6 and n-3 fatty acids, LA and ALA.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.